Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010 | Zendy

Rodrigo E. Mendes | Zendy; Leah N. Woosley | Zendy; David J. Farrell | Zendy; Hélio S. Sader | Zendy; Ronald N. Jones | Zendy

Open Access

Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010

Author(s) -

Rodrigo E. Mendes,

Leah N. Woosley,

David J. Farrell,

Hélio S. Sader,

Ronald N. Jones

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.06067-11

Subject(s) - vancomycin , microbiology and biotechnology , glycopeptide , minimum inhibitory concentration , enterococcus faecalis , enterococcus faecium , enterococcus , chemistry , biology , antibiotics , bacteria , staphylococcus aureus , genetics

Oritavancin exhibited potent activity against vancomycin-susceptible (MIC50 and MIC90 , 0.015/0.03 μg/ml) andvanB -carryingE. faecalis isolates (MIC50 and MIC90 , 0.015 and 0.015 μg/ml). Higher (16- to 32-fold) MIC50 s and MIC90 s forvanA -harboringE. faecalis were noted (MIC50 and MIC90 , 0.25 and 0.5 μg/ml), although oritavancin inhibited all strains at ≤0.5 μg/ml. Vancomycin-susceptible andvanB -carryingE. faecium strains (MIC50 and MIC90 , ≤0.008 and ≤0.008 μg/ml for both) were very susceptible to oritavancin, as were VanA-producing isolates (MIC50 and MIC90 , 0.03 and 0.06 μg/ml). Oritavancin exhibited goodin vitro potency against this collection of organisms, including vancomycin-resistant enterococci.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research